TCRX Q2 2023 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TCRXTScan Therapeutics, Inc.

$69M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-22.4% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$25M-781.8% margin

Net Income

-$24M-763.8% margin

EPS (Diluted)

$-0.51

QoQ Revenue Growth

-53.7%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$22M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$317M

Total Liabilities

$126M

Stockholders' Equity

$191M

Cash & Equivalents

$209M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$4M	-22.4%
Gross Profit	$3M	-$10M	+130.2%
Operating Income	-$25M	-$15M	-61.4%
Net Income	-$24M	-$15M	-59.3%